Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With <i>BRCA</i>-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial
Domenica Lorusso(Agostino Gemelli University Polyclinic), Giovanni Scambia(Agostino Gemelli University Polyclinic), Grazia Artioli(Ospedale di Mirano), Carmela Pisano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Anna Maria Mosconi(Azienda Ospedaliera di Perugia), Dominique Ronzulli(Fondazione IRCCS Istituto Nazionale dei Tumori), Vanda Salutari(Agostino Gemelli University Polyclinic), Germana Tognon(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Enrico Breda(Fatebenefratelli Hospital), Stefano Tamberi(Ospedale per gli Infermi), Cláudia Casanova, Filippo Greco(University of Catania), Chiara Cassani(University of Pavia), Serafina Mammoliti(Ospedale Policlinico San Martino), Claudia Andreetta(Ospedale Santa Maria della Misericordia di Udine), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giorgio Valabrega(CTO Hospital), Serena Giolitto(Agostino Gemelli University Polyclinic), Rita Ceccherini(University of Trieste), Francesco Raspagliesi(Fondazione IRCCS Istituto Nazionale dei Tumori), Nicoletta Colombo(University of Milano-Bicocca), Giorgia Mangili(Vita-Salute San Raffaele University)
Cited by 3
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k